{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T19:16:33Z","timestamp":1788203793952,"version":"build-2803163510"},"reference-count":15,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"DOI":"10.15420\/ecr.2026.41","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:34:27Z","timestamp":1787682867000},"source":"Crossref","is-referenced-by-count":0,"title":["Lipoprotein(a): It is Time to Understand and Treat this Cardiovascular Risk Factor"],"prefix":"10.15420","author":[{"given":"Derek","family":"Connolly","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02smq5q54","id-type":"ROR","asserted-by":"publisher"}],"name":"Birmingham City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaimini","family":"Cegla","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05jg8yp15","id-type":"ROR","asserted-by":"publisher"}],"name":"Hammersmith Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Bork C, Nordestgaard BG, Hedegaard BS, et al. Lipid clinics worldwide: harmonization and guidance on how to optimally organize and fund. European Atherosclerosis Society consensus statement across 55 countries and more than 500 lipid clinics. Atherosclerosis 2026;418:120757. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120757; PMID: 42178198. DOI: 10.1016\/j.atherosclerosis.2026.120757","DOI":"10.1016\/j.atherosclerosis.2026.120757"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Kataoka Y, Ray KK, Nicholls SJ, et al. Lipoprotein(a) and residual cardiovascular risks in Japanese patients with coronary artery disease who achieve guideline-recommended low-density lipoprotein cholesterol goals. Eur Heart J 2026. https:\/\/doi.org\/10.1093\/eurheartj\/ehag446; PMID: 42177636; epub ahead of press. DOI: 10.1093\/eurheartj\/ehag446","DOI":"10.1093\/eurheartj\/ehag446"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Lim LC, Al-Jarshawi M, Chew NWS, et al. Lipoprotein(a) distribution across race\/ethnicity and association with mortality outcomes in NHANES III (1988 to 1994) with follow\u2011up to 2019. Am J Cardiol 2026;272:20\u20138. https:\/\/doi.org\/S0002-9149(26)00316-4. https:\/\/doi.org\/10.1016\/j.amjcard.2026.04.063; PMID: 42097262. DOI: 10.1016\/j.amjcard.2026.04.063","DOI":"10.1016\/j.amjcard.2026.04.063"},{"key":"ref3","unstructured":"Connolly D, Antoniou A, Cegla J, et al. A UK Federated Lp(a) Data Network: interim findings of Lp(a) testing rates in UK secondary care. Presented at: European Atherosclerosis Society Annual Meeting, Athens, Greece, 24\u20137 May 2026."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Fichtner I, Macchi C, Rizzuto AS, et al. Lipoprotein(a) and the atherosclerotic burden \u2013 should we wait for clinical trial evidence before taking action? Atheroscler Plus 2024;58:16\u201323. https:\/\/doi.org\/10.1016\/j.athplu.2024.09.004; PMID: 39435317. DOI: 10.1016\/j.athplu.2024.09.004","DOI":"10.1016\/j.athplu.2024.09.004"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Cho L, Nordestgaard BG, Chang B, et al. Concordance of lipoprotein(a) measurements in mg\/dL and nmol\/L: insights from the Lp(a)HORIZON trial. Atherosclerosis 2026:418;120796. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120796; PMID: 42250319. DOI: 10.1016\/j.atherosclerosis.2026.120796","DOI":"10.1016\/j.atherosclerosis.2026.120796"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Kao AS, Kermanshahchi J, Khosrowjerdi S, et al. Demographics of lipoprotein(a) and stroke: the UK Biobank. Am J Prev Cardiol 2025;23:101055. https:\/\/doi.org\/10.1016\/j.ajpc.2025.101055; PMID: 40687939. DOI: 10.1016\/j.ajpc.2025.101055","DOI":"10.1016\/j.ajpc.2025.101055"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Kronenberg F, Bedlington N, Ademi Z, et al. The Brussels International Declaration on Lipoprotein(a) Testing and Management. Atherosclerosis 2025;406:119218. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119218; PMID: 40340180. DOI: 10.1016\/j.atherosclerosis.2025.119218","DOI":"10.1016\/j.atherosclerosis.2025.119218"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Patel D, Koschinsky ML, Agarwala A, et al. Role of lipoprotein(a) in atherosclerotic cardiovascular disease in South Asian individuals. J Am Heart Assoc 2025;14:eJAHA2024040361T. https:\/\/doi.org\/10.1161\/JAHA.124.040361; PMID: 40654252. DOI: 10.1161\/JAHA.124.040361","DOI":"10.1161\/JAHA.124.040361"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Taageby Nielsen S, Mohr Lytsen R, Strandkj\u00e6r N, et al. Significance of lipids, lipoproteins, and apolipoproteins during the first 14\u201316 months of life. Eur Heart J 2023;44:4408\u201318. https:\/\/doi.org\/10.1093\/eurheartj\/ehad547; PMID: 37632410. DOI: 10.1093\/eurheartj\/ehad547","DOI":"10.1093\/eurheartj\/ehad547"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Bhatia HS, Ambrosio M, Razavi AC, et al. AHA PREVENT equations and lipoprotein(a) for cardiovascular disease risk : insights from MESA and the UK Biobank. JAMA Cardiol 2025;10:810\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2025.1603; PMID: 40465279. DOI: 10.1001\/jamacardio.2025.1603","DOI":"10.1001\/jamacardio.2025.1603"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Cho L, Nicholls SJ, Nordestgaard BG, et al. Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a). Am Heart J 2025;287:1\u20139. https:\/\/doi.org\/10.1016\/j.ahj.2025.03.019; PMID: 40185318. DOI: 10.1016\/j.ahj.2025.03.019","DOI":"10.1016\/j.ahj.2025.03.019"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Gurevitz C, Bajaj A, Khera AV, et al. Gene therapy and genome editing for lipoprotein disorders. Eur Heart J 2025;46:3420\u201333. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf411; PMID: 40600248. DOI: 10.1093\/eurheartj\/ehaf411","DOI":"10.1093\/eurheartj\/ehaf411"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Nicholls SJ, Nelson AJ, Ray KK, et al. Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials. Eur Heart J 2026:47:3404\u201314. https:\/\/doi.org\/10.1093\/eurheartj\/ehag399; PMID: 42183881. DOI: 10.1093\/eurheartj\/ehag399","DOI":"10.1093\/eurheartj\/ehag399"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Desai MY, Braunwald E. The pathophysiologic basis and management of calcific aortic valve stenosis: JACC state-of-the-art review. J Am Coll Cardiol 2025;86:659\u201372. https:\/\/doi.org\/10.1016\/j.jacc.2025.06.049; PMID: 40866051. DOI: 10.1016\/j.jacc.2025.06.049","DOI":"10.1016\/j.jacc.2025.06.049"}],"container-title":["European Cardiology Review"],"original-title":[],"link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2026.41","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T19:02:12Z","timestamp":1788202932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2026.41"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":15,"URL":"https:\/\/doi.org\/10.15420\/ecr.2026.41","relation":{},"ISSN":["1758-3756","1758-3764"],"issn-type":[{"value":"1758-3756","type":"print"},{"value":"1758-3764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"e49"}}